Abstract
CC and CXC chemokines coinduced in fibroblasts and leukocytes by cytokines and microbial agents determine the number of phagocytes infiltrating into inflamed tissues. Interleukin-8/CXCL8 and stromal cell-derived factor-1/CXCL12 significantly and dose-dependently increased the migration of monocytes, expressing the corresponding CXC chemokine receptors CXCR2 and CXCR4, toward suboptimal concentrations of the monocyte chemotactic proteins CCL2 or CCL7. These findings were confirmed using different chemotaxis assays and monocytic THP-1 cells. In contrast, the combination of two CC chemokines (CCL2 plus CCL7) or two CXC chemokines (CXCL8 plus CXCL12) did not provide synergy in monocyte chemotaxis. These data show that chemokines competing for related receptors and using similar signaling pathways do not synergize. Receptor heterodimerization is probably not essential for chemokine synergy as shown in CXCR4/CCR2 cotransfectants. It is noteworthy that CCL2 mediated extracellular signal-regulated kinase 1/2 phosphorylation and calcium mobilization was significantly enhanced by CXCL8 in monocytes, indicating cooperative downstream signaling pathways during enhanced chemotaxis. Moreover, in contrast to intact CXCL12, truncated CXCL12(3-68), which has impaired receptor signaling capacity but can still desensitize CXCR4, was unable to synergize with CCL2 in monocytic cell migration. Furthermore, AMD3100 and RS102895, specific CXCR4 and CCR2 inhibitors, respectively, reduced the synergistic effect between CCL2 and CXCL12 significantly. These data indicate that for synergistic interaction between chemokines binding and signaling of the two chemokines via their proper receptors is necessary.
Footnotes
-
This work was supported by the European Union 6FP EC contract INNOCHEM, by the Interuniversity Attraction Poles Programme-Belgian State-Belgian Science Policy, the Fund for Scientific Research of Flanders (Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, Belgium), the Concerted Research Actions of the Regional Government of Flanders and the Center of Excellence of the University of Leuven (Credit no. EF/05/15; Rega Institute). M.G., S.S., and E.S. are senior research assistants from the Fund for Scientific Research of Flanders.
-
ABBREVIATIONS: GPCR, G protein-coupled receptor; fMLP, N-formyl-l-methionyl-l-leucyl-l-phenylalanine; IFN, interferon; LPS, lipopolysaccharide; IL, interleukin; MCP, monocyte chemotactic protein; CCR, CC chemokine receptor; CHO, Chinese hamster ovary; ERK, extracellular signal-regulated kinase; PBMC, peripheral blood mononuclear cell; ConA, concanavalin A; PIC, polyriboinosinic:polyribocytidylic acid; FCS, fetal calf serum; MEM, minimal essential medium; CI, chemotactic index; BSA, bovine serum albumin; ELISA, enzyme-linked immunosorbent assay; ROI, region(s) of interest; FACS, fluorescence-activated cell sorting; PBS, phosphate-buffered saline; TLR, Toll-like receptor; RS102895, 1′-[2-[4-(trifluoromethyl)phenyl]ethyl]-spiro[4H-3,1-benzoxazine-4,4′-piperidin]-2(1H)-one; AMD3100, 1,1′-(1,4-phenylenebis-(methylene))-bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride dihydrate; PI3K, phosphatidylinositol 3-kinase.
- Received January 11, 2008.
- Accepted May 9, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|